A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Clinical trial NCT05879978 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05879978
Sponsor: Boehringer Ingelheim
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms

Start date: 2023-06-27
Primary completion: 2025-06-11
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.